NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

  • STATUS
    Recruiting
  • participants needed
    120
  • sponsor
    Medesis Pharma SA
Updated on 8 February 2023

Summary

This is a prospective, multicenter, randomized (3:1), placebo- controlled, parallel-group, double-blind trial.

Patients will be randomized into two arms of treatment:

  • Placebo + SoC (N=30)
  • NanoManganese® + SoC (N=90)

Patients will be treated and followed-up for 10 days:

  • Arterial oxygen partial pressure (PaO2) will be measured at baseline and at days 3, 5 and 10,
  • Oxygen saturation, vital signs including respiration rate, pulse rate, blood pressure and body temperature, disease severity (7-point ordinal scale and NEWS2 score) will be measured at baseline and daily,
  • Hematology and biochemistry measurements will be done at baseline and at day 3, 5 and 10,
  • Pharmacokinetic (Blood Mn concentration) measurements will be done at baseline and at day 3, 5 and 10,
  • Biomarkers will be measured at baseline and at day 3, 5 and 10. At the end of the 10-day treatment period, a follow-up visit will be planned between day 15 and day 22. The following.

assessments/examinations will be performed: oxygen saturation, vital signs including respiration rate and body temperature, disease severity (7-point ordinal scale and NEWS2 score), electrocardiogram (ECG), hematology, biochemistry, concomitant therapies, and adverse events.

Description

120 patients will be enrolled in this study, they will be randomly assigned in 2 arms on a 3:1 ratio, 90 patients in the NanoManganese®

+ Standard of Care group and 30 patients in the placebo + Standard of Care group.

This study will be conducted in Brazil and will be conducted in around 8 investigational sites

The investigational products are :

Manganese sulfate monohydrate, MnSO4, H2O (NanoManganese®) will be administered using the microemulsion AONYS® technology. The product is mucoadhesive, it sticks to the mucosa of the cheeks on which it will be deposited and will not be swallowed.

The placebo (Pharmacopoeia soybean oil) will be administered using the same protocol and the same bottle.

Treatments :

NanoManganese® + standard of care group:

  • NanoManganese®: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
  • Standard of care

Placebo + standard of care group:

  • Placebo: administration of 2 mL twice a day (morning and evening) by depositing 1 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
  • Standard of care The treatments will be administered by the nurse. Duration of treatment: 10 days or until hospital discharge or until death.

Details
Condition COVID-19 Pandemic
Treatment Placebo, Experimental drug
Clinical Study IdentifierNCT05451654
SponsorMedesis Pharma SA
Last Modified on8 February 2023

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note